Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Polihexanide→

Polihexanide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
32289-58-0
Molecular formula
[C8H17N5]n
Molecular weight
Not available
Drug class
Polymeric biguanide antiseptictopical antimicrobial and wound-cleansing agent
Mechanism of action
The positively charged guanidine groups bind to negatively charged phospholipids in microbial cell membranes, compromising membrane integrity, causing leakage of cytoplasmic components and leading to microbial cell death. Some formulations also support wound-bed cleansing and healing.
Indications / reported uses
  • Antiseptic cleansing and management of acute or chronic wounds with products authorised for wound irrigation or topical use.
  • Antimicrobial cleansing of selected burns, ulcers and colonised wounds according to the specific product instructions.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polihexanide-solution · https://pubmed.ncbi.nlm.nih.gov/26949863/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Polihexanide Environmental Risk Assessment (ERA) (the Polihexanide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.